LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.
Read more at prnewswire.comAadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20SoFi%20logo%20on%20an%20office%20building%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/Stickers%20with%20AMD%20Radeon%20and%20Nvidia%20GeForce%20RTX%20graphics%20on%20new%20laptop%20computer%20by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
